146 related articles for article (PubMed ID: 37732631)
1. Clinical and cytogenetic characteristics of primary and secondary plasma cell leukemia under the new IMWG definition criteria: a retrospective study.
Guan J; Ma J; Chen B
Hematology; 2023 Dec; 28(1):2254556. PubMed ID: 37732631
[TBL] [Abstract][Full Text] [Related]
2. Clinicopathological and laboratory parameters of plasma cell leukemia among Indian population.
Dubey H; Goel H; Verma S; Gupta S; Tanwar K; Rahul E; Kapoor G; Vasantharaman J; Ranjan A; Tanwar P; Chopra A
Am J Blood Res; 2022; 12(6):190-195. PubMed ID: 36742277
[TBL] [Abstract][Full Text] [Related]
3. Bortezomib-based Regimens Improve the Outcome of Patients with Primary or Secondary Plasma Cell Leukemia: A Retrospective Cohort Study.
Wang H; Zhou H; Zhang Z; Geng C; Chen W
Turk J Haematol; 2020 May; 37(2):91-97. PubMed ID: 31769277
[TBL] [Abstract][Full Text] [Related]
4. Genetic aberrations and survival in plasma cell leukemia.
Tiedemann RE; Gonzalez-Paz N; Kyle RA; Santana-Davila R; Price-Troska T; Van Wier SA; Chng WJ; Ketterling RP; Gertz MA; Henderson K; Greipp PR; Dispenzieri A; Lacy MQ; Rajkumar SV; Bergsagel PL; Stewart AK; Fonseca R
Leukemia; 2008 May; 22(5):1044-52. PubMed ID: 18216867
[TBL] [Abstract][Full Text] [Related]
5. Genetic profile of primary plasma cell leukemia in Korea: comparison with plasma cell myeloma.
Lee Y; Yun J; Jeong D; Ryu S; Kwon SR; Yun H; Kim SM; Park JH; Lee DS
Leuk Lymphoma; 2022 Feb; 63(2):385-394. PubMed ID: 34592901
[TBL] [Abstract][Full Text] [Related]
6. The Cytogenetic Profile of Primary and Secondary Plasma Cell Leukemia: Etiopathogenetic Perspectives, Prognostic Impact and Clinical Relevance to Newly Diagnosed Multiple Myeloma with Differential Circulating Clonal Plasma Cells.
Papadhimitriou SI; Terpos E; Liapis K; Pavlidis D; Marinakis T; Kastritis E; Dimopoulos MA; Tsitsilonis OE; Kostopoulos IV
Biomedicines; 2022 Jan; 10(2):. PubMed ID: 35203419
[TBL] [Abstract][Full Text] [Related]
7. Plasma cell leukemia: a rare condition.
Jiménez-Zepeda VH; Domínguez VJ
Ann Hematol; 2006 Apr; 85(4):263-7. PubMed ID: 16416115
[TBL] [Abstract][Full Text] [Related]
8. [Effect of Circulating Plasma Cells on the Prognosis of Patients with Multiple Myeloma].
Li F; Gao YJ; Li SS; Xi YY; Yang XW; Su YH
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2023 Dec; 31(6):1771-1779. PubMed ID: 38071059
[TBL] [Abstract][Full Text] [Related]
9. [Clinical Characteristics and Survival Analysis of Patients with Plasma Cell Leukemia].
Wang SF; Qin XQ; Guo QH; Wang JY; Ma YP
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2023 Jun; 31(3):693-698. PubMed ID: 37356928
[TBL] [Abstract][Full Text] [Related]
10. Multiple myeloma patients with low proportion of circulating plasma cells had similar survival with primary plasma cell leukemia patients.
An G; Qin X; Acharya C; Xu Y; Deng S; Shi L; Zang M; Sui W; Yi S; Li Z; Hao M; Feng X; Jin F; Zou D; Qi J; Zhao Y; Tai YT; Wang J; Qiu L
Ann Hematol; 2015 Feb; 94(2):257-64. PubMed ID: 25231928
[TBL] [Abstract][Full Text] [Related]
11. [The clinical characteristics of patients with primary plasma cell leukemia and the efficacy of novel agents and hematopoietic stem cell transplantation].
Li WJ; Wang FR; Wen L; Chen Y; Chen H; Huang XJ; Lu J
Zhonghua Nei Ke Za Zhi; 2020 Oct; 59(10):801-806. PubMed ID: 32987483
[No Abstract] [Full Text] [Related]
12. The clinical characteristics and prognosis of patients with primary plasma cell leukemia (pPCL) according to the new IMWG definition criteria.
Yan W; Fan H; Xu J; Liu J; Li L; Du C; Deng S; Sui W; Hao M; Yi S; Zou D; Qiu L; Xu Y; An G
Leuk Lymphoma; 2022 Dec; 63(12):2955-2964. PubMed ID: 35819882
[TBL] [Abstract][Full Text] [Related]
13. Primary Plasma Cell Leukemia: Real-World Retrospective Study of 46 Patients From a Single-Center Study in China.
Yu T; Xu Y; An G; Tai YT; Ho M; Li Z; Deng S; Zou D; Yu Z; Hao M; Anderson KC; Qiu L
Clin Lymphoma Myeloma Leuk; 2020 Oct; 20(10):e652-e659. PubMed ID: 32624447
[TBL] [Abstract][Full Text] [Related]
14. Treatment with bortezomib-based regimens improves overall response and predicts for survival in patients with primary or secondary plasma cell leukemia: Analysis of the Greek myeloma study group.
Katodritou E; Terpos E; Kelaidi C; Kotsopoulou M; Delimpasi S; Kyrtsonis MC; Symeonidis A; Giannakoulas N; Stefanoudaki A; Christoulas D; Chatziaggelidou C; Gastari V; Spyridis N; Verrou E; Konstantinidou P; Zervas K; Dimopoulos MA
Am J Hematol; 2014 Feb; 89(2):145-50. PubMed ID: 24123068
[TBL] [Abstract][Full Text] [Related]
15. Single-center experience of patients with plasma cell leukemia in the era of new therapeutics.
Dampmann M; Flossdorf S; Keyl J; Reinhardt HC; Hanoun C
Acta Haematol; 2024 May; ():. PubMed ID: 38763126
[TBL] [Abstract][Full Text] [Related]
16. Survival outcomes of patients with primary plasma cell leukemia (pPCL) treated with novel agents.
Mina R; Joseph NS; Kaufman JL; Gupta VA; Heffner LT; Hofmeister CC; Boise LH; Dhodapkar MV; Gleason C; Nooka AK; Lonial S
Cancer; 2019 Feb; 125(3):416-423. PubMed ID: 30332496
[TBL] [Abstract][Full Text] [Related]
17. Genetic aberrations including chromosome 1 abnormalities and clinical features of plasma cell leukemia.
Chang H; Qi X; Yeung J; Reece D; Xu W; Patterson B
Leuk Res; 2009 Feb; 33(2):259-62. PubMed ID: 18676019
[TBL] [Abstract][Full Text] [Related]
18. The Current State of Knowledge About Evolution of Multiple Myeloma to Plasma Cell Leukemia.
Jurczyszyn A; Olszewska-Szopa M; Vesole DH
Clin Lymphoma Myeloma Leuk; 2023 Mar; 23(3):188-193. PubMed ID: 36593169
[TBL] [Abstract][Full Text] [Related]
19. Clinical features and outcomes of plasma cell leukemia: a single-institution experience in the era of novel agents.
Talamo G; Dolloff NG; Sharma K; Zhu J; Malysz J
Rare Tumors; 2012 Jun; 4(3):e39. PubMed ID: 23087795
[TBL] [Abstract][Full Text] [Related]
20. Acquired del(9)(p22.3) in a primary plasma cell leukemia.
Achkar WA; Wafa A; Aljapawe A; Othman MA; Alhourani E; Liehr T
Mol Cytogenet; 2013 Aug; 6(1):33. PubMed ID: 23985162
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]